Guillain–Barré syndrome (GBS) is a rare autoimmune disorder, affecting as many as 6,000 people each year in the United States, but its risk increases with age. In the U.S., it’s most commonly seen in ...

MONTREAL — An investigational targeted immunotherapy for Guillain-Barré syndrome (GBS) more than doubled improvement in disability after 8 weeks compared with placebo and showed sustained benefit at ...

GBS is a condition in which the body’s immune system attacks the nerves, leading to weakness, numbness and, in severe cases, difficulty in breathing or walking.